# A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Source: https://onco.cc/trials/nct03729245/  
OnCo record `nct03729245` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Bempegaldesleukin, Sunitinib, Nivolumab and Cabozantinib in Renal cell carcinoma, run by Nektar Therapeutics, recorded as terminated on the registry.

## Summary

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) is a phase 3 interventional study registered as NCT03729245 by Nektar Therapeutics, with 623 participants recorded, started 2018-12-18 and due to reach its primary completion in 2022-01-07. Interventions recorded: bempegaldesleukin, sunitinib, nivolumab, cabozantinib. Conditions recorded: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma.

Linked to the drug Bempegaldesleukin because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03729245
- Phase: 3
- Setting: A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
- Sponsor: Nektar Therapeutics
- Enrolled: 623

## Sources

- ClinicalTrials.gov NCT03729245: https://clinicaltrials.gov/study/NCT03729245

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Bempegaldesleukin](https://onco.cc/drugs/bempegaldesleukin/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Sunitinib](https://onco.cc/drugs/sunitinib/)
- companies: [Nektar Therapeutics](https://onco.cc/companies/nektar-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct03729245.json